Graviton BioScience Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 43

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $5M

  • Investors
  • 6

Graviton BioScience General Information

Description

Developer of clinical-stage drugs designed for the treatment of autoimmune, cancer, and other serious diseases. The company is dedicated to engineering and developing therapeutics for treating CNS, autoimmune, fibrotic, and other serious diseases, where its other therapeutic compounds play a pivotal role in pathology and offer drug candidates targeting Rho-associated protein kinase, enabling patients to potentially access groundbreaking treatments for a range of debilitating diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 125 West End Avenue
  • Suite 301
  • New York, NY 10023
  • United States
+1 (646)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Corporate Office
  • 125 West End Avenue
  • Suite 301
  • New York, NY 10023
  • United States
+1 (646)

Graviton BioScience Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Graviton BioScience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 12-Nov-2026 $5M Completed Clinical Trials - Phase 3
3. Early Stage VC (Series B1) 14-Feb-2024 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 04-Dec-2023 $64.8M $68.3M Completed Clinical Trials - Phase 2
1. Seed Round 19-Feb-2021 $3.5M $3.5M Completed Pre-Clinical Trials
To view Graviton BioScience’s complete valuation and funding history, request access »

Graviton BioScience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-1
Series A-1C
Series A-1B
Series A-1A 9,466,507 $0.000100 $0.25 $3.15 $3.15 1x $3.15 22.06%
Series A 866,336 $0.000100 $4.04 $4.04 1x $4.04 2.02%
To view Graviton BioScience’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Graviton BioScience Patents

Graviton BioScience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250289807-A1 Inhibitors of rock2 Pending 29-Apr-2022
US-20240366604-A1 Selective inhibitors of rock2 for the treatment of muscular dystrophy Pending 28-Apr-2021

Graviton BioScience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Graviton BioScience Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Deep Future Venture Capital Minority
Innova Capital Partners Growth/Expansion Minority
Cormorant Asset Management PE/Buyout Minority
Enavate Sciences Venture Capital Minority
Ovid Therapeutics Corporation Minority
You’re viewing 5 of 6 investors. Get the full list »

Graviton BioScience Investments (1)

Graviton BioScience’s most recent deal was a Joint Venture with CinRock Pharma. The deal was made on 02-Nov-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CinRock Pharma 02-Nov-2026 Joint Venture Drug Discovery
To view Graviton BioScience’s complete investments history, request access »

Graviton BioScience FAQs

  • When was Graviton BioScience founded?

    Graviton BioScience was founded in 2020.

  • Where is Graviton BioScience headquartered?

    Graviton BioScience is headquartered in New York, NY.

  • What is the size of Graviton BioScience?

    Graviton BioScience has 43 total employees.

  • What industry is Graviton BioScience in?

    Graviton BioScience’s primary industry is Drug Discovery.

  • Is Graviton BioScience a private or public company?

    Graviton BioScience is a Private company.

  • What is Graviton BioScience’s current revenue?

    The current revenue for Graviton BioScience is .

  • How much funding has Graviton BioScience raised over time?

    Graviton BioScience has raised $98.3M.

  • Who are Graviton BioScience’s investors?

    Deep Future, Innova Capital Partners, Cormorant Asset Management, Enavate Sciences, and Ovid Therapeutics are 5 of 6 investors who have invested in Graviton BioScience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process